Table 1 Correlation between CALR mutations detected by Sanger Sequencing and CAL2-immunohistochemistry in samples obtained from bone marrow of patients with myeloproliferative neoplasms or other disorders and from control tissues
Disease type | No. of samples | No. of cases with detected mutations | |
|---|---|---|---|
Sanger sequencing | CAL2 IHC | ||
MPN NOS | 17 | 12 | 12 |
PMF | 52 | 20 | 20 |
ET | 59 | 20 | 20 |
PV | 19 | 0 | 0 |
Myeloid neoplasms other than PV, ET and PMF | 8 | ||
RARS-T | 1 | 0 | 0 |
MDS with fibrosis | 1 | 0 | 0 |
RAEB-1 | 1 | 0 | 0 |
CNL | 1 | 0 | 0 |
CML | 1 | 0 | 0 |
aCML | 1 | 0 | 0 |
Mastocytosis | 2 | 0 | 0 |
BM with non-myeloid neoplasm | 8 | ||
CLL | 3 | 0 | 0 |
MCL | 1 | 0 | 0 |
HCL | 1 | 0 | 0 |
PTCL | 1 | 0 | 0 |
cHL | 1 | 0 | 0 |
MGUS | 1 | 0 | 0 |
Non-neoplastic tissue | 10 | ||
BM in Iron deficiency | 1 | 0 | 0 |
BM in idiopathic thrombocyopenia | 1 | 0 | 0 |
Normal BM | 4 | 0 | 0 |
Tonsils | 4 | 0 | 0 |
Total No | 173 | 52 | 52 |
